The New Science of Aging: Why Your Organs Age at Different Rates with Paul Coletta

 What if the next major shift in fitness and health isn't another wearable or blood panel, but knowing which of your organs is aging fastest, and whether the things you're doing to improve your health are actually working?

Paul Coletta is Co-Founder and CEO of Vero Bioscience, a predictive health company commercializing Stanford research in proteomic organ aging.

Before Vero, Paul spent decades building consumer businesses and brands across Disney, MTV, Hewlett-Packard, Jamba Juice and Urban Remedy. He isn't an MD or a PhD. Three years ago, he says he didn't even know what proteomics was.

Then he became one of the first people to take what would become Vero's assay.

The result showed that his kidney was aging significantly faster than his chronological age, even though the traditional markers he had been tracking, including creatinine and GFR, looked normal. Paul didn't believe the result, so he took it to his cardiologist. An ultrasound found a large renal cyst. It was benign, but the experience changed how he thought about what health data could tell us before traditional diagnostics flag a problem.

That story became part of a much bigger question: Can we move from measuring health after something has gone wrong to seeing where the body may be heading, then intervene early enough to change the trajectory?

Eric Malzone and Paul unpack the emerging science behind proteomics, the study of proteins and what they can reveal about the real-time function of the body. Paul explains why he thinks proteins offer a different layer of information than genetics, conventional bloodwork and whole-body biological age scores.

Vero's Proteomic OrganAge™ analyzes roughly 11,000 proteins from a blood sample and maps those signals across 11 organ systems. The underlying research has been validated across more than 45,000 people, with longitudinal data extending over 17 years. Rather than reducing someone to a single biological-age number, the goal is to identify which parts of the body may be aging differently from the rest.

As Paul puts it: "You're only as healthy as your oldest organ."

But the measurement itself is only part of the conversation.

Eric has talked for years about the industry's "now what" problem: consumers have more data than ever from wearables, bloodwork, sleep trackers and other diagnostics, but getting another score doesn't necessarily tell someone what to do next.

Paul argues that the real opportunity is creating a closed-loop health system: measure what is happening, connect that insight to a targeted intervention, retest, and measure how the biology responds.

This leads to a broader conversation about the longevity industry itself.

As those categories continue to converge, the opportunity may be bigger than collecting more health data. It may be building systems that can turn that data into direction and give both consumers and clinicians a clearer picture of where to act next.


CONNECT WITH PAUL + VERO
Learn more about Vero Bioscience / join the waitlist →
https://www.verobioscience.com/?utm_source=future_of_fitness&utm_medium=podcast&utm_campaign=podcast_collective&utm_content=paul_coletta
Paul Coletta on LinkedIn →
https://www.linkedin.com/in/paulcoletta/
Vero Bioscience on LinkedIn →
https://www.linkedin.com/company/vero-bioscience-inc/home/